Latest period
$109.56M
YoY change
-33.0%
5Y CAGR
+37.6%
Peak year (2024)
$150.92M
Latest annual
$101.08M
Cash on Hand history chart for Climb Bio (CLYM) from 2019 to 2025
Latest: $101.08M
Cash on Hand growth chart for Climb Bio (CLYM) from 2019 to 2025
Latest: -33.0%
Cash on Hand history table for Climb Bio (CLYM) from 2019 to 2025
| 2025 | $101.08M | -33.0% | −$49.84M | ||
| 2024 | $150.92M | +41.3% | +$44.12M | ||
| 2023 | $106.80M | -13.6% | −$16.77M | ||
| 2022 | $123.57M | -9.5% | −$12.91M | ||
| 2021 | $136.48M | +566.2% | +$115.99M | ||
| 2020 | $20.49M | -3.5% | −$736.00K | ||
| 2019 | $21.22M | — | — |
- 2025$101.08M-33.0%
- 2024$150.92M+41.3%
- 2023$106.80M-13.6%
- 2022$123.57M-9.5%
- 2021$136.48M+566.2%
- 2020$20.49M-3.5%
- 2019$21.22M—
Cash on Hand values are taken from Climb Bio's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Cash on Hand at Climb Bio (CLYM)
According to Climb Bio's latest reported financial statements, the company's latest reported cash and short-term investments is $109.56M. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for net leverage and total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Climb Bio (CLYM) most recent annual cash and short-term investments stands at $101.08M (2025) – plunged 33.0% year-over-year.
Through 2020–2025 (5 years), Climb Bio cash and short-term investments delivered a +37.6% annualised rate; with mixed annual results across the window.
Between 2024 and 2025, Climb Bio cash and short-term investments plunged 33.0%, falling from $150.92M to $101.08M.
2024 marks the peak cash and short-term investments at $150.92M, with the historical low of $20.49M recorded in 2020.
Climb Bio Cash on Hand by Year
Climb Bio Cash on Hand 2025: $101.08M
In 2025, Climb Bio reported cash and short-term investments of $101.08M, plunged 33.0% below 2024.
Climb Bio Cash on Hand 2024: $150.92M
Climb Bio cash and short-term investments in 2024 was $150.92M, surged 41.3% from 2023. This figure represents the highest annual value in the available history.
Climb Bio Cash on Hand 2023: $106.80M
2023's cash and short-term investments for Climb Bio came in at $106.80M, declined 13.6% below 2022.
Climb Bio Cash on Hand 2022: $123.57M
Climb Bio posted cash and short-term investments of $123.57M in 2022, declined 9.5% below 2021.
Climb Bio Cash on Hand 2021: $136.48M
Climb Bio cash and short-term investments in 2021 was $136.48M.
See more financial history for Climb Bio (CLYM).
Sector peers by Cash on Hand
Healthcare peers of Climb Bio (CLYM), ranked by their latest cash and short-term investments
| $28.12B | |
| $20.10B | |
| $14.56B | |
| $9.13B | |
| $7.27B | |
| $5.74B | |
| $5.26B | |
| $4.24B |
- $28.12B
- $20.10B
- $14.56B
- $9.13B
- $7.27B
- $5.74B
- $5.26B
- $4.24B
Frequently asked questions
Climb Bio (CLYM) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation